Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06979323 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

Name: Depemokimab Asthma Imaging and Bronchoscopy Sub-Study — clinical trial record (NCT06979323)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorGlaxoSmithKline

Started2024-07-19

View on ClinicalTrials.gov ↗

Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

Amendment history 2 changes detected by DataLookout

2026-07-03

Trial sites expanded: 43 → 50 locations

2026-04-24

Trial sites expanded: 3 → 43 locations

Trial Details

NCT Number	NCT06979323
Lead Sponsor	GlaxoSmithKline
Conditions	Asthma
Enrollment	150 participants
Start Date	2024-07-19
Primary Completion	2028-01-05 (estimated)
Study Completion	2028-02-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-02